ACIU News and Press, AC Immune SA From 11/02/23

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 Lausanne, Switzerland, November 02, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering pre...

FNCB Bancorp Inc. (FNCB) is expected to report for Q1 2024 Civista Bancshares Inc. (CIVB) is expected to report $0.6 for Q3 2023 ASLAN Pharmaceuticals Limited (ASLN) is expected to report $-0.85 for Q3 2023 Grupo Televisa S.A. (TV) is expected to report $0.02 for Q3 2023 Red River...

PRESS RELEASE AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic ACI-12589 1 delivers the first element of a precision medicine approach by enabling early an...

AC Immune SA (ACIU) is expected to report $0 for Q3 2023

AC Immune Announces Upcoming Presentations at the 16 th CTAD Conference Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upco...

2023-10-10 08:51:03 ET SMX (Security Matters)  ( SMX ) +109% Secures Majority Stake in True Gold Consortium. Mobilicom Limited ( MOB ) +47% . AC Immune  ( ACIU ) +15% . Immunic  ( IMUX ) +14% jumps after the bell on positive int...

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Co...

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05 , 202 3 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medici...

2023-08-04 07:59:55 ET AC Immune press release ( NASDAQ: ACIU ): Q2 GAAP EPS of -$0.20 beats by $0.02 . Cash position of CHF 93.0 million finances the Company into Q3 2024, excluding the benefit of anticipated milestone payments For further details see: AC Im...

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update Received FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer’s disease (AD) Enrollment in ongoing Phase 1b/2 ABATE study o...